Targinta

Executive Summary

Targinta AB is a Swedish biotechnology company focused on developing targeted antibody-based therapeutics for aggressive cancers. Founded in 2014 and based in Uppsala, the company leverages a unique target, integrin α10β1, which is highly expressed in cancers such as glioblastoma and triple-negative breast cancer. Targinta's pipeline includes antibody-drug conjugates (ADCs) and functional blocking monoclonal antibodies designed to exploit this target for enhanced tumor specificity and reduced off-target effects. As a private company with no disclosed funding or stage, Targinta remains in early development, but its novel approach addresses significant unmet needs in oncology. The company's focus on a well-validated yet underexploited integrin target positions it as a potential player in the ADC and biologic space, pending preclinical and clinical validation.

Upcoming Catalysts (preview)

• Q1 2027Completion of IND-enabling studies for lead ADC candidate40% success
• Q3 2026Presentation of preclinical efficacy data at a major oncology conference60% success
• Q2 2027Series A financing round to advance pipeline35% success